高级检索
当前位置: 首页 > 详情页

ZDHHC9 promotes colon tumor growth by inhibiting effector T cells

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Clinical Cancer Institute, Translational Medicine Center, Naval Medical University, Shanghai 200433, P.R. China. [2]Thoracic Surgery Department, The General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China. [3]Center of Translational Medicine, Naval Medical University, Shanghai 200433, P.R. China. [4]Department of Geriatrics, Changhai Hospital, Naval Medical University, Shanghai 200433, P.R. China.
出处:
ISSN:

关键词: zinc finger DHHC‑type palmitoyltransferase 9 immune infiltration programmed death‑ligand 1 JAK/STAT1 colon cancer

摘要:
Zinc finger DHHC-type palmitoyltransferase 9 (ZDHHC9) has been reported to play an important role in the occurrence and development of several types of cancer. However, its effects on colon cancer growth remain unclear. Using Gene Expression Profiling Interactive Analysis and Tumor Immune Estimation Resource, data obtained from The Cancer Genome Atlas were analyzed, and the results showed that ZDHHC9 was highly expressed in colon cancer and that patients with higher ZDHHC9 expression levels had a worse prognosis. Inhibition of ZDHHC9 expression promoted the proliferation of colon cancer cells in vitro but decreased their growth in vivo. Additionally, inhibition of ZDHHC9 expression in cancer cells enhanced CD8+ T cell-mediated cytotoxicity in vitro and increased CD8+ T infiltration and activation in vivo. Furthermore, ZDHHC9 promoted IFN-γ-induced JAK/STAT1 activation and upregulated programmed death-ligand 1 (PD-L1) expression in colon cancer cells. In conclusion, the present findings showed that ZDHHC9 promoted colon cancer growth by upregulating the expression of PD-L1 and inhibiting the function of CD8+ T cells.Copyright: © Chong et al.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2023]版:
Q3 ONCOLOGY
最新[2023]版:
Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]Clinical Cancer Institute, Translational Medicine Center, Naval Medical University, Shanghai 200433, P.R. China.
共同第一作者:
通讯作者:
通讯机构: [1]Clinical Cancer Institute, Translational Medicine Center, Naval Medical University, Shanghai 200433, P.R. China. [4]Department of Geriatrics, Changhai Hospital, Naval Medical University, Shanghai 200433, P.R. China. [*1]Clinical Cancer Institute, Translational Medicine Center, Naval Medical University, 800 Xiangyin Road, Shanghai 200433, P.R. China [*2]Department of Geriatrics, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai 200433, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy [2]Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma [3]Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews [4]Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment [5]PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma [6]Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension [7]Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer [8]High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma [9]Study on the effect of different durations of decalcification and depigmentation on programmed death ligand 1 immunohistochemical staining [10]Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy

资源点击量:43389 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号